Clinical Trials Browser

Phase 1 × Neuroendocrine Tumors × Nivolumab × Clear all

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Phase 1 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05266612 2024-08-09

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Phase 1 Recruiting

Neuroendocrine Tumors